Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O9LN
|
|||
| Former ID |
DNCL002164
|
|||
| Drug Name |
ME-143
|
|||
| Synonyms |
ME-143; 852536-39-1; VXHSDGZMRLGSEJ-UHFFFAOYSA-N; SCHEMBL243810; NV143; ME143; KB-145995; Z-3309; 3,4-bis(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-7-ol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Marshall Edwards
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18O4
|
|||
| Canonical SMILES |
C1C(C(C2=C(O1)C=C(C=C2)O)C3=CC=C(C=C3)O)C4=CC=C(C=C4)O
|
|||
| InChI |
1S/C21H18O4/c22-15-5-1-13(2-6-15)19-12-25-20-11-17(24)9-10-18(20)21(19)14-3-7-16(23)8-4-14/h1-11,19,21-24H,12H2
|
|||
| InChIKey |
VXHSDGZMRLGSEJ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2014; 32(1): 87-93. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.